141 related articles for article (PubMed ID: 37401187)
1. Prostate-specific membrane antigen positron emission tomography detected local failure after post-prostatectomy radiation therapy: Low rates of out-of-field recurrence validates current Australian prostate bed contouring guidelines.
Shakespeare TP; Yap SZL; Hsieh M; Tahir ARM; Armstrong S
J Med Imaging Radiat Oncol; 2023 Sep; 67(6):662-667. PubMed ID: 37401187
[TBL] [Abstract][Full Text] [Related]
2. Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes.
Horsley PJ; Koo CM; Eade T; Hsiao E; Emmett L; Brown C; Kneebone A; Hruby G
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):106-117. PubMed ID: 35716849
[TBL] [Abstract][Full Text] [Related]
3.
Sonni I; Dal Pra A; O'Connell DP; Ells Z; Benz M; Nguyen K; Yoon SM; Deng J; Smith C; Grogan T; Nickols NG; Cao M; Kishan AU; Calais J
J Nucl Med; 2023 Jun; 64(6):902-909. PubMed ID: 36759200
[TBL] [Abstract][Full Text] [Related]
4. PSMA-PET-guided dose-escalated volumetric arc therapy for newly diagnosed lymph node-positive prostate cancer: 5 Year outcomes following the FROGG and EviQ node-positive guidelines.
Yap SZL; Armstrong S; Aherne N; Shakespeare TP
J Med Imaging Radiat Oncol; 2023 Jun; 67(4):456-462. PubMed ID: 37186452
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Based Clinical Target Volume Delineation Guideline for Postprostatectomy Salvage Radiation Therapy: The PERYTON Guideline.
Staal FHE; Janssen J; Oprea-Lager DE; Engelen AM; van Limbergen EJ; Smeenk RJ; de Jong MAA; Budiharto TCG; Jacobs I; Haverkort DMAD; Brouwer CL; Ng Wei Siang K; Langendijk JA; Verzijlbergen JF; de Jong IJ; Noordzij W; Aluwini S
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):688-696. PubMed ID: 37729971
[TBL] [Abstract][Full Text] [Related]
6.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
7.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
8. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
9. Re-defining
Tissot S; Wynn J; Tran V; Farag M; Wong LM; Ng M
BJU Int; 2023 Oct; 132(4):411-419. PubMed ID: 37216190
[TBL] [Abstract][Full Text] [Related]
10. Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial.
Harmon G; Chan D; Lee B; Miller C; Gorbonos A; Gupta G; Quek M; Woods M; Savir-Baruch B; Harkenrider MM; Solanki AA
Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):1195-1203. PubMed ID: 34015368
[TBL] [Abstract][Full Text] [Related]
11. Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
Boreta L; Gadzinski AJ; Wu SY; Xu M; Greene K; Quanstrom K; Nguyen HG; Carroll PR; Hope TA; Feng FY
Urology; 2019 Jul; 129():165-171. PubMed ID: 30928607
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
[TBL] [Abstract][Full Text] [Related]
13. PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.
Schiller K; Stöhrer L; Düsberg M; Borm K; Devecka M; Vogel MME; Tauber R; Heck MM; Rauscher I; Eiber M; Gschwend JE; Duma MN; Combs SE
Eur Urol Oncol; 2021 Feb; 4(1):73-83. PubMed ID: 32451312
[TBL] [Abstract][Full Text] [Related]
14. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
[TBL] [Abstract][Full Text] [Related]
15. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
[TBL] [Abstract][Full Text] [Related]
16. Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation.
Imber BS; O'Dwyer E; Lobaugh S; McBride SM; Hopkins M; Kollmeier M; Gorovets D; Brennan V; Pike LRG; Gewanter R; Mychalczak B; Zhang Z; Schöder H; Zelefsky MJ
Urology; 2022 Dec; 170():146-153. PubMed ID: 36115426
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
18. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
Staal FHE; Janssen J; Brouwer CL; Langendijk JA; Ng Wei Siang K; Schuit E; de Jong IJ; Verzijlbergen JF; Smeenk RJ; Aluwini S
BMC Cancer; 2022 Apr; 22(1):416. PubMed ID: 35428210
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
